Oncoatlas

History

2024: Vadim Yakunin bought more than 70% of the cancer laboratory from the Atlas holding

At the end of June 2024, it became known that the Atlas biomedical holding sold a 71.5 percent stake in the Oncoatlas molecular oncology center. The buyer was Vadim Yakunin, the main owner of the Protek group of companies.

Oncoatlas was founded in 2011 under the name CSB Genomics, and in 2015 it became part of the Atlas holding. The center develops oncological care based on the unique features of each patient. To understand the full picture and make accurate clinical decisions, many factors are taken into account, including hereditary features and molecular genetic characteristics. The development of Oncoatlas includes reagent kits for determining the sequence of nucleotides (sequencing) of new generation DNA and RNA (NGS), as well as software for the automatic interpretation of mutations in major clinically relevant genes.

Unsplash

At the time of its completion, nothing is officially said about the amount of the transaction to sell a stake in Oncoatlas. According to Nikolai Bespalov, development director of the analytical company RNC Pharma, we can talk about "several tens of millions of rubles." After the completion of the transaction, the co-founder of Oncoatlas Vladislav Mileiko continues to own 28.5% of the laboratory's shares.

According to Mikhail Burmistrov, CEO of InfoLine Analytics, the acquisition of the asset by Yakunin may be due to the fact that Oncoatlas registered the first sets of reagents for the company's sequencer in June 2024. Helicon The development is expected to improve the company's operating performance and lead to multiple revenue growth. Executive Director of the Moscow Oncological Society Ivan Trotsenko adds that the molecular diagnostics market is actively growing following the development of personalized medicine, taking into account the genetic, physiological and biochemical features of a particular patient.^[1]

Notes